Innoviva, Inc.
No SEC Form 4 filings for $INVA in the last 30 days.
See all $INVA insider activity →Oppenheimer analysts identify FuelCell Energy (FCEL) and Innoviva (INVA) as stocks with significant upside potential. FCEL, with a $24 price target, is seen benefiting from data-center electricity demand, while INVA, with a $35 target, is undervalued in specialty therapeutics. Both stocks are rated Outperform, with potential gains of 42% and 66% respectively.
Innoviva, Inc. (INVA) reported Q2 revenue of $119.59 million, up from $100.28 million a year earlier, but shifted from net income of $63.69 million to a net loss of $83.42 million. Loss per share from continuing operations was $1.14. For six months, revenue rose to $217.59 million and net income to $103.18 million, and the company completed a $66.40 million buyback retiring 4.12% of shares.
Innoviva, Inc. (INVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INVA (Innoviva, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent INVA coverage spans financial news and earnings.
Analyst upgrade and price target imply potential upside for INVA.
The quarter shows earnings volatility despite capital return, which can pressure near-term sentiment until earnings quality stabilizes.
Q2 print plus updated 2026 IST U.S. net product sales target and a new Dr. Reddy’s commercialization deal are near-term catalysts for INVA’s revenue and cash-flow outlook.
Despite current weak sentiment, technical analysis indicates support levels and a strong long-term signal, suggesting potential for future gains.
Innoviva reported significantly higher revenues and net income for Q4 and full-year 2025, with a notable EPS increase partly driven by a non-recurring gain. This boosts investor confidence but raises questions about earnings sustainability.
AlphAI scores every news story that mentions INVA with an AI model for sentiment and relevance, and aggregates insider trades from Innoviva, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer analysts identify FuelCell Energy (FCEL) and Innoviva (INVA) as stocks with significant upside potential. FCEL, with a $24 price target, is seen benefiting from data-center electricity demand, while INVA, with a $35 target, is undervalued in specialty therapeutics. Both stocks are rated Outperform, with potential gains of 42% and 66% respectively.
2 min readInnoviva, Inc. (INVA) reported Q2 revenue of $119.59 million, up from $100.28 million a year earlier, but shifted from net income of $63.69 million to a net loss of $83.42 million. Loss per share from continuing operations was $1.14. For six months, revenue rose to $217.59 million and net income to $103.18 million, and the company completed a $66.40 million buyback retiring 4.12% of shares.
6 min readInnoviva, Inc. (INVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress IST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter
7 min readInnoviva Inc. (NASDAQ: INVA) is showing weak near and mid-term sentiment despite a long-term positive outlook. AI models have generated three distinct trading strategies with a notable 36.0:1 risk-reward setup targeting a 9.7% gain against 0.3% risk. The analysis indicates various support and resistance levels across different time horizons, with a strong signal for the long term.
4 min readInnoviva, Inc. reported significantly higher fourth-quarter and full-year 2025 revenues and net income, with a sharp increase in EPS from continuing operations, attributed partly to a large non-recurring gain. This earnings strength raises questions about its repeatability and influences Innoviva's investment narrative, with its share price rising but still potentially undervalued. Investors should consider the sustainability of these earnings and the tension between strong past performance and future profit forecasts.
3 min readInnoviva (INVA) concluded FY 2025 with strong Q4 revenues and EPS, but its 65.9% net profit margin was significantly boosted by a US$161.6 million one-off gain. This challenges bullish narratives, as analysts predict an earnings decline over the next three years, and the company's five-year annualized earnings have declined by 22.1%. The low P/E ratio of 6.5x, compared to an industry average of 19.9x, is seen by some as reflecting softer long-term trends and non-recurring profits.
3 min readInnoviva (INVA) delivered earnings and revenue surprises of +134.78% and +14.78%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Scott Berg initiated coverage on Shopify Inc.
3 min readA report on April 23, 2025 shows that Representative George Whitesides from California sale stock in Innoviva INVA, valued between $2,222,033 and $5,180,000. According to the April filing, the transaction occurred on April 23, 2025. At the time of writing, Innoviva shares are trading down 0.0% at ...
2 min read
